Clinical Trial Update: A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A feasibility and safety study evaluating universal dual-specificity CAR-T cells targeting CD19/CD20 or CD22 for relapsed or refractory B cell leukemia and lymp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Leukemia
• B-cell Lymphoma

Drugs mentioned

• universal dual specificity CD19/CD20 or CD22 CAR-T cell immunotherapy

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: B Cell Leukemia, B Cell Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN